1. Home
  2. BFST vs MGTX Comparison

BFST vs MGTX Comparison

Compare BFST & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Business First Bancshares Inc.

BFST

Business First Bancshares Inc.

HOLD

Current Price

$27.98

Market Cap

877.1M

Sector

Finance

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$9.21

Market Cap

909.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFST
MGTX
Founded
2006
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
877.1M
909.1M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
BFST
MGTX
Price
$27.98
$9.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
7
Target Price
$32.75
$24.57
AVG Volume (30 Days)
141.8K
646.7K
Earning Date
04-27-2026
05-12-2026
Dividend Yield
2.23%
N/A
EPS Growth
23.45
33.02
EPS
0.68
N/A
Revenue
$10,704,000.00
$81,391,000.00
Revenue This Year
$22.71
$141.38
Revenue Next Year
$5.02
N/A
P/E Ratio
$41.16
N/A
Revenue Growth
1.20
144.57
52 Week Low
$22.56
$5.02
52 Week High
$30.32
$11.85

Technical Indicators

Market Signals
Indicator
BFST
MGTX
Relative Strength Index (RSI) 55.01 46.35
Support Level $26.73 $8.75
Resistance Level $28.74 $9.65
Average True Range (ATR) 0.53 0.43
MACD 0.08 -0.09
Stochastic Oscillator 75.72 21.87

Price Performance

Historical Comparison
BFST
MGTX

About BFST Business First Bancshares Inc.

Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: